RETINOIDS, both naturally occurring and synthetic analogues of vitamin A, have been shown to have several effects experimentally that might be beneficial in the treatment of cancer. These include the labilization of membranes, an increase in cell adhesiveness, an increase in humoral and cell-mediated immunity, inhibition of cell growth and induction of differentiation (Lotan, 1980) . The last effect has been demonstrated in nullipotent mouse embryonal carcinoma cells (Jetten & Jetten, 1979) . Differentiation has also been noted in human teratomas after cytotoxic chemotherapy (Hong et al., 1977) but it is not known whether retinoids can induce "benign" differentiation in human teratomas.
Cell-culture experiments have shown growth inhibition or delay of many types of tumours from different species after addition of retinoids (Lotan, 1980) . However, growth inhibition in vivo has been shown in few of the animal tumours tested (Trown et al., 1976; Kistler & Peter, 1979) . There have been reports of basal-cell carcinomas and melanomas metastatic to skin responding to high-dose topical retinoids, and there is a report of basal-cell carcinomas responding to oral therapy (Bollag & Ott, 1971; Levine & Meyskens, 1980; Peck et al., 1979) . Mickshe et al. (1977) suggest that the growth of squamous-cell carcinoma of the lung was slowed in 9 patients by vitamin A therapy.
Accepted 26 October 1981 We have studied 24 patients with various solid tumours, including 7 with metastatic teratomas, to determine whether retinoid therapy could inhibit growth or induce differentiation of human tumours. The synthetic aromatic retinoid etretinate ("Tigason"; ethyl all-trans-9-(4-methoxy-2, 3,6-trimethylphenyl)-3, 7-dimethyl-2, 4, 6, 8-nonatetraenoate), which has been found to be useful in several dermatological conditions (Lancet Editorial, 1981) was used in this study.
Twenty-four patients with histologically proven advanced neoplasms which were refractory to conventional treatment (including cytotoxic chemotherapy) were entered into this study. (Figure 1 ).
Two patients with advanced ovarian adenocarcinoma had stabilization of their disease, as assessed by palpation and CT scans, for 12 and 17 weeks, but there was evidence of progression at 17 and 21 weeks respectively. Table II gives more detail of the 6 patients with testicular teratomas. There was X-ray evidence oftumour enlargement in all, and levels of either AFP, hCG or both markers rose in 5 patients whilst receiving etretinate. Several different histological types of malignant teratoma were treated, and at second-look operations after cytotoxic chemotherapy 3/6 showed evidence of tumour differentiation. However, only one of the'3 patients showing differentiation received etretinate before surgery and he (RR) had histological examination both before and after etretinate. Histology of the para-aortic mass removed after cytotoxic chemotherapy showed differentiated teratoma with some embryonal elements and rhabdomyoblasts. After 9 weeks of etretinate treatment alone, an enlarging mediastinal mass was removed, which showed differentiated teratoma with immature cartilage and rhabdomyoblasts.
Four patients with malignant teratoma (2 with melanoma, one with Hodgkin's disease and one with non-Hodgkin's lymphoma) received a total of 19 courses of cytotoxic chemotherapy whilst receiving etretinate (Table III) . Marginal volume or tumour-marker responses were seen in 3 patients with teratomas. These responses were no greater than when the same combination (VP.16-213 + actinomycin D + cyclophosphamide; VP. 16-213+cis-platinum; cyclophosphamide + ci8-platinum) had been given without etretinate, and were of very short duration. Similarly, the response to radiotherapy of one patient with melanoma, one with non-Hodgkin's lymphoma and one with teratoma whilst receiving etretinate was no greater than when given without. Etretinate did not increase the toxicity of radiotherapy or cytotoxic chemotherapy.
This study showed that in 17/19 evaluable patients, their tumours progressed whilst receiving retinoid therapy. The aromatic retinoid etretinate was chosen for this trial because oral administration produces signs of hypervitaminosis A without liver toxicity. In addition, it has a better therapeutic ratio than other retinoids tested in animal systems (Mayer et al., 1978 embryonal carcinoma cells, its main acid metabolite was shown to be active, and there is a high serum concentration of this metabolite in vivo (Hanni et al., 1979) . Etretinate did not induce differentiation of the malignant teratomas in the 6 evaluable patients with this tumour. There was histological evidence of undifferentiated active teratoma in one of these patients after 9 weeks' retinoid therapy. In the other 5 patients, in addition to enlargement of their tumour masses, there was a rise in their tumour markers whilst on etretinate.
One of the patients in whom there was no progression of tumour whilst on etretinate had metastatica melanoma. When melanoma metastasizes to the brain it almost invariably runs a progressive course. It is unlikely that this woman's tumour was eradicated by the cranial irradiation and CCNU, since the CT scan has remained abnormal throughout her treatment. Although it cannot be certain from one case that retinoid therapy may be beneficial in patients with metastatic melanoma, it is worth a trial in melanoma patients in view of its minimal toxicity and the absence of other successful treatment. The apparent temporary halt in disease progression in 2 patients with ovarian adenocarcinoma could be explained by the inadequacy of methods for monitoring this tumour.
Vitamin A was shown to enhance the antitumour effect of BCNU against murine L1210 leukaemia by Cohen & Carbone (1972) who suggested that this was related to their combined effects on membranes. No enhancement was shown in the present study, even with the lipidsoluble agents CCNU and VP.16-213.
Retinoids have many interesting properties, but this study suggests that much more experimental work is needed before a place can be found for them in human cancer chemotherapy.
Since this paper was prepared similar results have been reported in abstract form, using 1 3-cis retinoic acid in advanced cancer (Meyskens et al., 1981) .
